AbbVie Submits Supplemental New Drug Application to U.S. FDA to Support New Indication of LINZESS® for Functional Constipation in Children and Adolescents 6 to 17 Years of Age Pharmaceutical Investing
Gilead Sciences: Latinas Contra Cancer Empowers Patients To Advocate for Change Pharmaceutical Investing
Bristol Myers Squibb to Report Results for Fourth Quarter 2022 on February 2, 2023 Pharmaceutical Investing
AstraZeneca and Merck Provide Update on US Regulatory Review of LYNPARZA® in Combination With Abiraterone and Prednisone or Prednisolone as Treatment of Metastatic Castration-Resistant Prostate Cancer Life Science Investing
Johnson & Johnson Announces Extension of Abiomed Tender Offer to December 21, 2022 Pharmaceutical Investing
Abbott and the Brain Injury Association of America launch Concussion Awareness Now coalition; team up with Rebel Wilson to raise awareness on seriousness of concussions Pharmaceutical Investing
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA , Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial Life Science Investing
Three-Year Follow-Up Analysis of Kite's Yescarta® CAR T-cell Therapy - 52% of Patients With Indolent Lymphomas Continued to Have Ongoing Responses at a Median Follow-Up of 40.5 Months Pharmaceutical Investing
New Analyses of Kite's Tecartus® CAR T-Cell Therapy Provide Additional Evidence Supporting Overall Survival and Durability of Response Pharmaceutical Investing
